Overview
- PATHFINDER 2 analyzed 23,161 asymptomatic adults with at least 12 months’ follow‑up, reporting 61.6% positive predictive value and 99.6% specificity.
- Overall sensitivity in participants followed for more than a year was 40.4%, with detection stronger for a subgroup of 12 cancers that shed more tumor DNA.
- The test identified the likely tissue of origin in 92% of confirmed cases, streamlining subsequent diagnostic work‑ups.
- More than half of Galleri‑detected new cancers were stage I–II (53.5%), and 69.3% were stage I–III, with roughly three‑quarters from cancers lacking standard screening.
- Adding Galleri to recommended screening increased cancers found within a year by more than sevenfold, as the NHS continues a >140,000‑person trial with topline results expected next year and experts calling for mortality and cost‑effectiveness data before broad rollout.